Jill Hoffman, PhD

Dr. Hoffman’s current research is focused on the in vitro and in vivo mechanisms underlying communication between the enteric nervous system and the intestinal epithelium during inflammation. She received her Ph.D. in Neuroscience from The University of Vermont in 2012 where she studied 5-HT4 receptors in the intestinal mucosa and inflammation-induced neuroplasticity during colitis. Her previous work at UCLA has shown a novel role for corticotropin-releasing hormone receptor 2 (CRHR2) signaling in mucosal repair responses following colitis.

Ongoing projects in the laboratory include the study of CRH signaling in the initiation of protective responses by enteric glial cells (EGCs) during colitis, as well as studies designed to understand mechanisms of crosstalk between EGCs and the intestinal epithelium during inflammation. In addition, recent work has identified pro-proliferative actions of Inflammatory Bowel Disease patient-derived human mesenteric adipose tissue-derived stromal cells (ADSCs) on intestinal epithelial cells.

Dr. Hoffman is currently funded by a CURE/CTSI Pilot and Feasibility Studies Award, a Research Grant from the American Neurogastroenterology and Motility Society, and the American Gastroenterological Association-Takeda Pharmaceuticals Research Scholar Award in Inflammatory Bowel Disease.